Exec Chat: Medtronic Neuromodulation Approaches Inflection Point
Medtech Insight talked to Ashwini Sharan, the new chief medical officer for Medtronic's neuromodulation business, and and Nnamdi Njoku, the president of the business, to learn about the company's vision for neuromodulation technology and how the company can leverage its particular strengths make these therapies more effective and accessible.
You may also be interested in...
Nevro Attacks Pain And Competition With Individualized AI-Enabled Spinal Cord Stimulator
The company is selling the Senza HFX iQ spinal cord stimulation system across the US following a successful limited market release.
Abbott’s Plan For DBS Depression Therapy Wins FDA’s Breakthrough Designation
Abbott continued St. Jude Medical’s prior research on deep brain stimulation for treating depression and has advanced the technology far enough that the US FDA now believes it could be a breakthrough treatment for treatment-resistant depression.
NeuroMetrix Gets FDA De Novo Authorization For Neuromodulation Device To Treat Fibromyalgia
NeuroMetrix plans to market the prescription-based Quell in the fourth quarter to US rheumatologists and pain medicine physicians.